Core Viewpoint - The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, which will ensure patient access through the government health system in England and Wales [1] Company Summary - Alnylam Pharmaceuticals has received a positive recommendation from the UK's drug cost-effectiveness watchdog for its heart disease drug [1] - This recommendation is significant as it facilitates access for patients within the government health system in England and Wales [1] Industry Summary - The decision by the UK's drug cost-effectiveness watchdog highlights the ongoing evaluation of drug cost-effectiveness in the healthcare system [1] - The approval of new heart disease treatments is crucial for addressing the growing health concerns related to cardiovascular diseases in the UK [1]